11 research outputs found
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a devastating disease affecting about 1 out of 5000 male births and caused by mutations in the dystrophin gene. Genome editing has the potential to restore expression of a modified dystrophin gene from the native locus to modulate disease progression. In this study, adeno-associated virus was used to deliver the CRISPR/Cas9 system to the mdx mouse model of DMD to remove the mutated exon 23 from the dystrophin gene. This includes local and systemic delivery to adult mice and systemic delivery to neonatal mice. Exon 23 deletion by CRISPR/Cas9 resulted in expression of the modified dystrophin gene, partial recovery of functional dystrophin protein in skeletal myofibers and cardiac muscle, improvement of muscle biochemistry, and significant enhancement of muscle force. This work establishes CRISPR/Cas9-based genome editing as a potential therapy to treat DMD
Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases
Targeted gene addition to mammalian genomes is central to biotechnology, basic research and gene therapy. For example, gene targeting to the ROSA26 locus by homologous recombination in embryonic stem cells is commonly used for mouse transgenesis to achieve ubiquitous and persistent transgene expression. However, conventional methods are not readily adaptable to gene targeting in other cell types. The emerging zinc finger nuclease (ZFN) technology facilitates gene targeting in diverse species and cell types, but an optimal strategy for engineering highly active ZFNs is still unclear. We used a modular assembly approach to build ZFNs that target the ROSA26 locus. ZFN activity was dependent on the number of modules in each zinc finger array. The ZFNs were active in a variety of cell types in a time- and dose-dependent manner. The ZFNs directed gene addition to the ROSA26 locus, which enhanced the level of sustained gene expression, the uniformity of gene expression within clonal cell populations and the reproducibility of gene expression between clones. These ZFNs are a promising resource for cell engineering, mouse transgenesis and pre-clinical gene therapy studies. Furthermore, this characterization of the modular assembly method provides general insights into the implementation of the ZFN technology
Feline Lectin Activity Is Critical for the Cellular Entry of Feline Infectious Peritonitis Virusāæ
Feline infectious peritonitis is a lethal disease of felids caused by systemic infection with a feline coronavirus. Here, we report identification and analysis of the feline homologue to the human lectin DC-SIGN and show that it is a coreceptor for virulent strains of serotype 1 and serotype 2 feline coronaviruses
Enhanced MyoD-Induced Transdifferentiation to a Myogenic Lineage by Fusion to a Potent Transactivation Domain
Genetic reprogramming
holds great potential for disease modeling,
drug screening, and regenerative medicine. Genetic reprogramming of
mammalian cells is typically achieved by forced expression of natural
transcription factors that control master gene networks and cell lineage
specification. However, in many instances, the natural transcription
factors do not induce a sufficiently robust response to completely
reprogram cell phenotype. In this study, we demonstrate that protein
engineering of the master transcription factor MyoD can enhance the
conversion of human dermal fibroblasts and adult stem cells to a skeletal
myocyte phenotype. Fusion of potent transcriptional activation domains
to MyoD led to increased myogenic gene expression, myofiber formation,
cell fusion, and global reprogramming of the myogenic gene network.
This work supports a general strategy for synthetically enhancing
the direct conversion between cell types that can be applied in both
synthetic biology and regenerative medicine
Therapeutic genome editing: prospects and challenges
Available in PMC 2015 July 06Recent advances in the development of genome editing technologies based on programmable nucleases have substantially improved our ability to make precise changes in the genomes of eukaryotic cells. Genome editing is already broadening our ability to elucidate the contribution of genetics to disease by facilitating the creation of more accurate cellular and animal models of pathological processes. A particularly tantalizing application of programmable nucleases is the potential to directly correct genetic mutations in affected tissues and cells to treat diseases that are refractory to traditional therapies. Here we discuss current progress toward developing programmable nucleaseābased therapies as well as future prospects and challenges.Robert MetcalfeSimons FoundationMerkin Family Foundation for Stem Cell ResearchNational Science Foundation (U.S.) (NSF Waterman Award)National Science Foundation (U.S.) (NSF Graduate Research Fellowship, grant number 1122374)National Institute of General Medical Sciences (U.S.) (Award number T32GM007753)National Institutes of Health (U.S.) ((NIH) Directorās Pioneer Award (DP1-MH100706))W. M. Keck FoundationNational Institute of Neurological Disorders and Stroke (U.S.) (NIH Transformative R01 grant (R01-NS 07312401))Damon Runyon Cancer Research FoundationSearle Scholars ProgramEsther A. & Joseph Klingenstein Fund, Inc.Vallee Foundatio